RecruitingNCT05868928

Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis

Imaging Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis (IRRAS-BM)


Sponsor

Asan Medical Center

Enrollment

132 participants

Start Date

Dec 7, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • Patients who underwent stereotactic radiosurgery (SRS, gamma-knife radiosurgery or cyberknife radiosurgery) for brain metastases
  • Patients with lesions eligible for SRS :
  • One to ten newly diagnosed brain metastases
  • Patients without acute neurological symptom
  • Patients with a Karnofsky performance status score of 70 or higher
  • Patients who underwent brain MRI within 1 month of enrollment
  • Patients with measurable enhancing lesions on MRI.
  • Patients who have available reference standard (second-look surgery for recurrence) or available follow up imaging for clinic-radiologic reference standard.
  • A longest diameter \> 1.5 cm for tumor habitat analysis.

Exclusion Criteria5

  • Patients who have undergone prior brain surgery, SRS, or whole-brain radiation therapy.
  • Patients who are diagnosed with leukemia, lymphoma, germ-cell tumor, small-cell lung cancer, leptomeningeal disease, or unknown primary tumor.
  • Patients with age \< 18 years.
  • Patients without baseline MRI.
  • Patients with nonmeasurable enhancing lesions on MRI : all other lesions, including lesions with longest dimension \< 10 mm, lesions with borders that cannot be reproducibly measured, dural metastases, bony skull metastases, and leptomeningeal disease.

Interventions

DIAGNOSTIC_TESTMagnetic resonance imaging (MRI)

Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image

DIAGNOSTIC_TESTDiffusion-weighted MRI

Diffusion-weighted MRI

DIAGNOSTIC_TESTArterial spin labeling (ASL)

Cerebral blood flow imaging parameter

DIAGNOSTIC_TESTDynamic susceptibility contrast-MRI (DSC-MRI)

Cerebral blood volume and vessel architectural imaging parameters


Locations(1)

Asan Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05868928


Related Trials